Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics

Kyle LaHucik

Senior Reporter

Atea Pharmaceuticals, which went public in the fall of 2020 with the hopes of treating Covid-19 and other infectious diseases but has since struggled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

China’s biotech market is staging a comeback that US biotech can only wish for

Genentech vet launches ADC startup with $20M

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Atea con­firms un­so­licit­ed cash pro­pos­al from Tang Cap­i­tal’s Con­cen­tra, the shell buy­ing Jounce Ther­a­peu­tics

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics